US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VanEck Vectors Coal ETF

94.92

0.0000

Volume:- -

Turnover:- -

Market Cap:35.12M

PE:- -

High:94.92

Open:94.92

Low:94.92

Close:94.92

Loading ...

Overview Company News Filings

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

CZ has reduced the price of his ReachMe private message to 0.8 BNB

0xSun: The Golden Age of Shorting Shitcoins is Over

Industry Giants Such as Li Lin, CZ, Justin Sun, and Others Gathered in Hong Kong Last Night to Attend an Industry Meetup

Analysis: ACT Flash Crash Incident Binance adjusted the leverage position limit for ACT, causing liquidation of the market maker's overleveraged position at market price

Press Release: BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

CZ: Received approximately $24,000 in consultation fees via ReachMe over the past two days

SlowMist: ReachMe Previously Had a Message Fee Bypass Vulnerability, Allowing Users to Send Messages to CZ at a Low Cost

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

Cryptocurrency KOL Ansem has joined time.fun by creating an account.

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Press Release: Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Amnis has announced the launch of its governance token AMI, with 8% of the total supply to be airdropped to early adopters.

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

This Week in Review | Binance Initiates Listing and Delisting Voting; Identity of '50x Leverage' Whale Revealed

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Crypto KOL: WhiteRock appears to be launched by a team with a history of rug pulls, users should be cautious

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KOL/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KOL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KOL\",,,,,undefined,":{"symbol":"KOL","market":"US","secType":"STK","nameCN":"VanEck Vectors Coal ETF","latestPrice":94.92,"timestamp":1607979600000,"preClose":94.92,"halted":4,"volume":0,"delay":0,"floatShares":370000,"shares":370000,"eps":0,"marketStatus":"Delisted","change":0,"latestTime":"12-14 16:00:00 EST","open":94.92,"high":94.92,"low":94.92,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750406400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":94.92,"sharesOutstanding":370000,"nav":95.75227,"aum":35428340.72,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KOL\",,,,,undefined,":{"symbol":"KOL","floatShares":370000,"roa":"--","roe":"--","lyrEps":0,"shares":370000,"dividePrice":0,"high":94.92,"amplitude":0,"preClose":94.92,"low":94.92,"week52Low":54.099,"pbRate":"--","week52High":111,"institutionHeld":0,"latestPrice":94.92,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":94.92},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KOL\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525993228","title":"Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2525993228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525993228?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057520/0/en/Opus-Genetics-Announces-One-Month-Clinical-Data-from-Pediatric-Patient-in-Phase-1-2-Trial-of-OPGx-LCA5-Gene-Therapy-in-Inherited-Retinal-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","KOL","BK4023","IE00BZ1G4Q59.USD","BK4588","SAP","IE00BHPRN162.USD","IRD","LU0170899867.USD","BK4585","LU0971096721.USD","LU0149725797.USD","CMC","IE00BKVL7J92.USD","LCA","BK4613","IE00B1BXHZ80.USD","LU0267386448.USD","LU0882574139.USD","LU1363072403.SGD","BK4007","BK4528"],"gpt_icon":0},{"id":"2525851022","title":"CZ has reduced the price of his ReachMe private message to 0.8 BNB","url":"https://stock-news.laohu8.com/highlight/detail?id=2525851022","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525851022?lang=en_us&edition=fundamental","pubTime":"2025-04-08 15:57","pubTimestamp":1744099020,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 8th, CZ has reduced his private message price on the paid chat platform ReachMe from 1 BNB to 0.8 BNB.BlockBeats previously reported that on March 28th, CZ stated, \"According to Dune data, I have received approximately $24,000 in the past two days through the paid chat platform ReachMe under the BNB Chain ecosystem. The platform has a total of 3,262 users, including 1,358 KOL users . Currently, I have received some valuable advice, and each message is charged at 1 BNB.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/288784","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["KOL"],"gpt_icon":0},{"id":"2525062236","title":"0xSun: The Golden Age of Shorting Shitcoins is Over","url":"https://stock-news.laohu8.com/highlight/detail?id=2525062236","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525062236?lang=en_us&edition=fundamental","pubTime":"2025-04-07 15:54","pubTimestamp":1744012440,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 7th, Smart Money, crypto KOL 0xsun.sol  posted on social media, stating, \"For the past two months, I have been consistently shorting altcoins with low leverage. My strategy has gradually shifted to diversified targets and reduced single-position size. The reason is: old coins have plummeted in value, new coins, after experiencing a round of valuation slaughter, do not exhibit a clear market cap bubble, making it difficult to sustain a continued decline with high rebound risk. At the same time, more and more funds are shorting, and some market makers have started controlling the market to squeeze out short positions or using funding rates to counterattack, weakening the advantage of shorting.I believe the golden age of shorting altcoins has passed, and it is not suitable for inexperienced players to participate. Regarding buying the dip, the current macro changes  have triggered further declines, but the bottom is not yet clear, and further observation is needed.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/288623","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["APT.USD.HKCC","TON.USD.CC","APT.USD.CC","TON.USD.HKCC","KOL"],"gpt_icon":0},{"id":"2525805285","title":"Industry Giants Such as Li Lin, CZ, Justin Sun, and Others Gathered in Hong Kong Last Night to Attend an Industry Meetup","url":"https://stock-news.laohu8.com/highlight/detail?id=2525805285","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525805285?lang=en_us&edition=fundamental","pubTime":"2025-04-07 12:16","pubTimestamp":1743999360,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 7th, Cryptocurrency KOL @cryp_orange shared a post stating, \"Last night, Nano Labs founder Kong Jianping hosted a gathering, Li Lin was the host, CZ was the main guest, with participants including Xiao Feng, Justin Sun, Shen Bo, Cai Wensheng, Yang Linke, Ba Er Ye, and other OGs.\" According to the released on-site group photo, the list of attendees is as follows:Li Lin, Founder of Xinhuo TechnologyCZ, Founder of BinanceShen Bo, Partner at Distributed CapitalXiao Feng, Chairman of Wanxiang BlockchainJustin Sun, Founder of TRONKong Jianping, Founder of Nano LabsYi Lihua, Founder of Ledao CapitalChu Xiahu, Chairman of Yuanjie FoundationCai Wensheng, Founder of MeituYang Linke, Co-founder of BTC China, etc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/288583","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BTC","BTC.USD.HKCC","XBTmain","KOL","BTCmain"],"gpt_icon":0},{"id":"2524711823","title":"Analysis: ACT Flash Crash Incident\nBinance adjusted the leverage position limit for ACT, causing liquidation of the market maker's overleveraged position at market price","url":"https://stock-news.laohu8.com/highlight/detail?id=2524711823","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524711823?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:55","pubTimestamp":1743508500,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 1st: Crypto KOL and former FTX community partner Benson Sun posted on social media today, analyzing that \"At 18:30 today, ACT suddenly experienced a flash crash of 50%. The cause was Binance adjusting the leverage position limit for ACT, where a single leverage can only open a position of up to $4.5 million. Some market maker positions exceeded the limit and were directly liquidated at market price. After the contract price collapsed, a huge price difference appeared between the contract and spot, causing the spot market to also crash.\"This time Binance announced the change on April 1st at 15:32, with the change taking effect at 18:30 on April 1st, giving users less than 3 hours to react. What's even more absurd is that on March 31st, Binance had already announced a modification to ACT's position limit, and on April 1st, they further reduced the position limit for low leverage by 50%.Before modifying the rules, Binance should assess how many positions would be li","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/287818","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["APT.USD.HKCC","TON.USD.HKCC","APT.USD.CC","TON.USD.CC","KOL","ACT"],"gpt_icon":0},{"id":"2523917894","title":"Press Release: BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917894","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917894?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Conference call and webcast at 8:30 a.m. Eastern Time today. NEW YORK, March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update.-- December 30, 2024: Issued a letter to shareholders summarizing key. -- December 11, 2024: Hosted a key opinion leader  webinar featuring. Dr. Terry Heiman-Patterson, from the Lewis Katz School of Medicine. at Temple University. Dr. Heiman-Patterson discussed the current. treatment landscape and advances for patients with ALS . The replay. can be accessed on the corporate website here.-- November 11, 2024: Announced a strategic partnership with Pluri to. support manufacturing for the Phase 3b NurOwn trial, enhancing. -- October 30, 2024: Regained compliance with Nasdaq's minimum bid price. requirement, maintaining continued listing on the Nasdaq Capital Mar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU0098860793.USD","BK4127","LU1162221912.USD","LU2028103732.USD","LU0149725797.USD","BK4232","IE00B1BXHZ80.USD","LU0971096721.USD","LU1363072403.SGD","LU0314104364.USD","BK4006","LU2111349929.HKD","LU1548497426.USD","LU2347655156.SGD","BK4581","LU0795875086.SGD","IE00BZ1G4Q59.USD","LU1989772840.SGD","LU0106831901.USD","LU1732799900.SGD","LU2357305700.SGD","IE00BHPRN162.USD","R","LENZ","KOL","LU0158827781.USD","LU2089283258.USD","LU1989772923.USD","LU2023251221.USD","BK4516","BK4504","LU0795875169.SGD","LU2133065610.SGD","BK4022","LU1668664300.SGD","BCLI","BK4585","LU0912757837.SGD","LU2089284900.SGD","LU1720051108.HKD","LU0320765646.SGD","LU0158827948.USD","LU1732800096.USD","LU1720051017.SGD","LU0106261372.USD","LU0267386448.USD","BK4588","LU2271345857.HKD","CMC"],"gpt_icon":0},{"id":"2523991415","title":"BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523991415","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523991415?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:30","pubTimestamp":1743417000,"startTime":"0","endTime":"0","summary":"BX211 produced sustained and statistically significant1 Percent Area Reduction  of ulcer size , with a separation from placebo starting at week 7 and a difference greater than 40% by week 10. Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13  , and in reducing the expansion of ulcer area .BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration  feedback. \"We believe these data represent one of the strongest demonstrations to date of the therapeutic potential of phage therapy. We are grateful to all the patients who participated, and the treating teams who enrolled patients into the study, as well as the continued and ongoing support from the U.S. Defense Health Agency  for this program,” said Jonathan Solomon, BiomX’s Chief Executive Officer. “Today, 30-40% of DFO cases lead to lower extremity amputations related to serious bacterial infections, accounting for the majority of the 160,000 l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biomx-announces-positive-topline-results-103000263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHGE","PAR","KOL","BK4139","BK4157"],"gpt_icon":0},{"id":"2522570783","title":"CZ: Received approximately $24,000 in consultation fees via ReachMe over the past two days","url":"https://stock-news.laohu8.com/highlight/detail?id=2522570783","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522570783?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:28","pubTimestamp":1743168480,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 28, Binance founder CZ stated on social media, \"According to Dune Analytics, in the past two days, I received approximately $24,000 through the fee-based messaging platform ReachMe under the BNB Chain ecosystem.\"\"The total number of platform users is 3262, with 1358 KOL users .\"\"Currently, I have received some valuable advice, with each message charging 1 BNB.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/287430","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["KOL"],"gpt_icon":0},{"id":"2522529650","title":"SlowMist: ReachMe Previously Had a Message Fee Bypass Vulnerability, Allowing Users to Send Messages to CZ at a Low Cost","url":"https://stock-news.laohu8.com/highlight/detail?id=2522529650","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522529650?lang=en_us&edition=fundamental","pubTime":"2025-03-28 18:12","pubTimestamp":1743156720,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 28th, recently SlowMist Security Team disclosed that a logic vulnerability was found in the subscription-based messaging platform ReachMe io in the BNB Chain ecosystem. This vulnerability could bypass the preset fee mechanism and allow sending messages to any KOL  at a very low cost.The researchers successfully sent a message to CZ with only 0.01 BNB, bypassing the original 1 BNB message fee. The vulnerability was due to the contract failing to verify the consistency between on-chain transfer amounts and the front-end set price. The vulnerability has since been promptly patched.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/287406","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["KOL","BK4120","TISI"],"gpt_icon":0},{"id":"2522537299","title":"BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537299","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537299?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., March 27, 2025  -- BioVie Inc. , , a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual investor event featuring key opinion leader  Lindsay McAlpine, MD, BSc , who will join company management to discuss the unmet need and current treatment landscape for long COVID on Thursday, April 10, 2025 at 10:00 AM ET. To register, click here.The event will provide an update on BioVie's ADDRESS-LC trial evaluating bezisterim  for the treatment of long COVID. Bezisterim is a novel, oral, blood-brain barrier–permeable, anti-inflammatory, insulin-sensitizing agent that has shown to selectively inhibit inflammation-driven ERK- and NF-κB-stimulated inflammatory mediators, without inhibiting their homeostatic functions. Chronic neuroinflammation, potentially driven by persisting viral spike protein1,2, is one of the main hypotheses that r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biovie-host-kol-investor-webcast-120000241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","LC","BK4588","BK4535","BK4551","HST","BK4218","BK4166","KOL","BNTX","BK4139","BIVI","BK4585","BK4568","BK4548"],"gpt_icon":0},{"id":"2522937895","title":"Cryptocurrency KOL Ansem has joined time.fun by creating an account.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522937895","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522937895?lang=en_us&edition=fundamental","pubTime":"2025-03-26 12:37","pubTimestamp":1742963820,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 26th, according to crypto KOL Ansem, he has opened a time.fun account. At the time of writing, its price per minute has reached $13.38.time.fun is a platform that tokenizes time, helping creators monetize their time. When a creator tokenizes their time, traders can buy, sell, and redeem that time within minutes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/287032","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["APT.USD.CC","KOL","TON.USD.HKCC","TON.USD.CC","APT.USD.HKCC"],"gpt_icon":0},{"id":"2522402225","title":"Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET","url":"https://stock-news.laohu8.com/highlight/detail?id=2522402225","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522402225?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertensionRADNOR, Pa., March  25, 2025  (GL","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048654/0/en/Mineralys-Therapeutics-to-Host-KOL-Call-to-Discuss-Clinical-Data-from-Launch-HTN-and-Advance-HTN-Pivotal-Trials-Tuesday-April-1-2025-at-8-00-AM-ET.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","BK4139","KOL","BK4561","BK4218","BK4581","ET","HST","BK4588","LENZ","BK4585","BK4181","BK4144","MLYS","AM"],"gpt_icon":0},{"id":"2522022501","title":"Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022501","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022501?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:00","pubTimestamp":1742896800,"startTime":"0","endTime":"0","summary":"- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning. - Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and backbone therapy potential. - Clinical proof of concept data from frontline AML trial under NCI CRADA, Actimab-A solid tumor program with PD-1 checkpoint inhibitors and Iomab-ACT commercial CAR-T trial together with other expected 2025 milestones to be outlined. - Actinium to highlight manufacturing infrastructure development activity to support revitalized clinical programs. Actinium's company update will highlight the 3 separate potential multi-billion-dollar blockbuster market opportunities being pursued with its targeted radiotherapies including the following:. - Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-kol-investor-100000655.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-kol-investor-100000655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4581","BK4588","CR","NCI","BK4181","BK4561","BK4144","KOL","BK4202","BK4161","HMA","BK4590","BK4585","ET","HST","BK4139","ATNM"],"gpt_icon":0},{"id":"2522707656","title":"Press Release: Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707656?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:05","pubTimestamp":1742846700,"startTime":"0","endTime":"0","summary":"Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomization. Existing cash position of $40.8 million expected to provide operating runway through Phase 3 topline results into 2026. Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the fiscal year ended December 31, 2024.Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, \"Our Phase 3 pivotal NEAT clinical trial has exceeded 50% enrollment with 71 participants screened and 61 randomized. Recent and upcoming new site activations are expected to accelerate enrollment through our target completion date in the second quarter of 2025. Assuming target enrollment completion, topline results from the NEAT study are anticipated in the fou","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","MAA","QNCX","LENZ","BK4215","CNS","BK4588","BK4135","KOL","BK4139"],"gpt_icon":0},{"id":"2521717804","title":"Amnis has announced the launch of its governance token AMI, with 8% of the total supply to be airdropped to early adopters.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521717804","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521717804?lang=en_us&edition=fundamental","pubTime":"2025-03-24 17:42","pubTimestamp":1742809320,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 24th, the Aptos ecosystem liquidity staking protocol Amnis Finance announced the launch of its governance token AMI. AMI token holders can vote on key decisions and implement changes within the protocol. These decisions may include setting the protocol fee structure, updating delegation strategies, establishing partnerships, and more.The core of this decision-making process is Amnis DAO governance. By participating in DAO governance voting, AMI holders help guide the development of Amnis Finance to make it more efficient and decentralized. The total supply of AMI is 1 billion tokens. Here is the distribution of the AMI token:· 15% Marketing - Used for incentive programs and future activities to attract and retain users;· 16% Ecosystem - Reserved for funding, partnerships, and other ecosystem initiatives;· 20% Team - Allocated to builders who have contributed to the growth of Amnis Finance and accelerated development;· 16% Investors  - Allocated to investors who p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/286756","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4120","DEX.AU","BK4211","APT.USD.HKCC","APT.USD.CC","BK7506","DAO","BK7095","KOL","TISI","ISBC","BK4510","BK4506","BK4204"],"gpt_icon":0},{"id":"2521778545","title":"UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521778545","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521778545?lang=en_us&edition=fundamental","pubTime":"2025-03-24 04:00","pubTimestamp":1742760000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., March 23, 2025  -- UNITY Biotechnology, Inc.  [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March 24, 2025, at 8:00 AM ET. To register, click here.About UBX1325UBX1325 is an investigational compound being studied in retinal diseases, including DME, and is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of BCL-xL, a member of the BCL-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. The Phase 2 BEHOLD study in patients with DME demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean BCVA through 48 weeks compared to sham treatment. In preclinical studies, UNITY has demonstrated that targeting BCL-xL with UBX1325 preferential","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unity-biotechnology-host-virtual-investor-200000520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["UNTY","BK4181","BK4211","BK4139","BK4218","BK4585","KOL","UBX","BK4588","HST"],"gpt_icon":0},{"id":"2521766012","title":"This Week in Review | Binance Initiates Listing and Delisting Voting; Identity of '50x Leverage' Whale Revealed","url":"https://stock-news.laohu8.com/highlight/detail?id=2521766012","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521766012?lang=en_us&edition=fundamental","pubTime":"2025-03-23 15:59","pubTimestamp":1742716740,"startTime":"0","endTime":"0","summary":"\"Movement Genesis: MoveDrop to Launch in April with Additional IncentivesMovement Labs co-founder Rushi Manche responded to recent airdrop controversies in a post on X, stating, \"MoveDrop is coming soon . Ahead of this, a few key issues need to be addressed: · Ensure TVL is bridged from Cornucopia, Parthenon is ready, there are no additional claiming conditions, guard against Sybil Activity, additional incentives. This will ensure a smooth and delay-free MoveDrop process.\"OKX DEX Aggregator Service Paused, Impacting Multiple API Trading BotsOn March 17, OKX officially announced tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/en/news/57419","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_highlight","symbols":["BTC.USD.CC","BK4601","SOL.USD.HKCC","BTC.USD.HKCC","TON.USD.CC","BK4594","KOL","ETH.USD.HKCC","APT.USD.CC","BK4588","ETH.USD.CC","BK4595","BK4600","TON.USD.HKCC","STRK","BK4596","BK4585","AAVE.USD.CC","AAVE.USD.HKCC","APT.USD.HKCC","BK4516","BK4023"],"gpt_icon":1},{"id":"2521649694","title":"Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2521649694","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521649694?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:01","pubTimestamp":1742500860,"startTime":"0","endTime":"0","summary":"TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046690/0/en/Tectonic-Therapeutic-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOL","TECX","BK4139"],"gpt_icon":0},{"id":"2520927182","title":"Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520927182","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520927182?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387400,"startTime":"0","endTime":"0","summary":"-  Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning. -  Clinical proof of concept data expected in 2H:2025 from Actimab-A combination with blockbuster immunotherapies KEYTRUDA and OPDIVO in solid tumor indications. - Actimab-A expanded into frontline AML in triplet combination with Venetoclax and ASTX-727, Taiho Oncology's hypomethylating agent, under NCI CRADA with initial clinical data expected by year-end 2025. - Iomab-ACT commercial CAR-T trial to initiate patient enrollment with clinical proof of concept data expected in 2H:2025; Iomab-ACT sickle cell disease trial expected to initiate in 1H:2025. Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and myelodysplastic syndromes  across multiple treatment settings. Sandesh Seth, Actinium's Chairman and CEO, said, \"We have made significant progress across our pipeline ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-investor-kol-123000877.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-investor-kol-123000877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BK4585","CR","HST","BK4181","BK4202","KOL","ACT","HMA","NCI","BK4588","BK4218","ATNM","BK4139"],"gpt_icon":0},{"id":"2519376923","title":"Crypto KOL: WhiteRock appears to be launched by a team with a history of rug pulls, users should be cautious","url":"https://stock-news.laohu8.com/highlight/detail?id=2519376923","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519376923?lang=en_us&edition=fundamental","pubTime":"2025-03-16 16:17","pubTimestamp":1742113020,"startTime":"0","endTime":"0","summary":"BlockBeats News: On March 16, according to crypto KOL Hebi, the on-chain brokerage project WhiteRock is suspected to be launched by the ZKasino team. Users should be cautious about security.ZKasino had previously rug pulled users for a total of 10,500 ETH (worth over $30 million at the time).","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/285770","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["APT.USD.CC","TON.USD.HKCC","ETH","KOL","APT.USD.HKCC","ETH.USD.HKCC","TON.USD.CC"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":94,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KOL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-12-15","symbol":"KOL","reason":null,"defaultRemindTime":1608042600000,"announcedDate":"2020-12-04","type":"delisting","dateTimestamp":1608008400000},{"market":"US","date":"2020-12-11","symbol":"KOL","amount":3.2432,"defaultRemindTime":1607697000000,"name":"Market Vectors-Coal ETF","payableDate":"2020-12-14","currency":"USD","type":"dividend","dateTimestamp":1607662800000},{"market":"US","date":"2020-04-15","symbol":"KOL","type":"split","dateTimestamp":1586923200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2019-12-23","symbol":"KOL","amount":0.939,"name":"Market Vectors-Coal ETF","payableDate":"2019-12-24","currency":"USD","type":"dividend","dateTimestamp":1577077200000},{"market":"US","date":"2018-12-20","symbol":"KOL","amount":0.824,"name":"Market Vectors-Coal ETF","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KOL\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":null,"paymentDate":null,"value":0.824,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":null,"value":0.939,"currency":"USD"},{"executeDate":"2020-12-11","recordDate":"2020-12-14","paymentDate":null,"value":3.2432,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KOL\",market:\"US\",delay:false,,,undefined,":{}}}